Akums Gains EU GMP and UK MHRA Certifications as FY26 Revenue Reaches Rs. 4,359 Crore

Dual regulatory certifications from EU GMP and UK MHRA authorities signal that Akums Drugs and Pharmaceuticals is repositioning its CDMO operations for European supply chains, not merely domestic volume growth. The certifications arrive alongside a Q4 FY26 revenue figure of Rs. 1,158 crore and a full-year revenue of Rs. 4,359 crore, with profit after tax surging 135% year-on-year.

For QA directors and plant heads at contract manufacturing organisations, the Akums trajectory illustrates the capital and compliance intensity required to sustain dual-jurisdiction certification. Achieving concurrent EU GMP status and MHRA approval demands that quality systems meet two overlapping but distinct inspection frameworks, a burden that has historically slowed Indian CDMOs from entering post-Brexit European supply arrangements. Akums' clearance on both fronts suggests its ICH Q10-aligned pharmaceutical quality system has been stress-tested against European inspectorate expectations.

The MHRA approval carries particular supply-chain relevance. Since Brexit, UK market access requires a separate conformity pathway from the EU route, meaning manufacturers must maintain parallel batch release and documentation protocols. Akums has now satisfied both, opening a lane for European partners seeking to diversify away from single-source supply agreements.

On the manufacturing side, the company reported that active Europe supplies have commenced, moving the certifications from compliance achievement into operational reality. For regulatory affairs leads benchmarking peer CDMOs, that distinction matters: certification without commercial offtake is a sunk cost; active supply validates the quality system under live GMP conditions and creates an inspection history that supports future site extensions or product additions.

The 135% PAT expansion across FY26 reflects margin improvement alongside revenue growth, though the source does not disaggregate the contribution of export business from domestic contract manufacturing. Plant heads evaluating capacity partnerships will note that financial resilience at this scale reduces counterparty risk in long-duration supply agreements.

The next measurable checkpoint will be whether Akums converts its European regulatory standing into named supply contracts that appear in partner disclosures or regulatory filings, which would confirm the quality investment is generating durable commercial return.

Source: Media4Growth via Indian Pharma Post, 17 May 2026.